Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467671 · ClinicalTrials.gov registry record · Phase 2
Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
A Phase 2 study of Cardiovascular Diseases and Single-ventricle, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04467671: Recruiting Phase 2 study of Cardiovascular Diseases and Single-ventricle, sponsored by Nationwide Children's Hospital.
NCT04467671 is a Phase 2 study of Cardiovascular Diseases and Single-ventricle that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 24 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04467671, a Phase 2 study of Cardiovascular Diseases and Single-ventricle, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
Primary Outcome
Assessed through graft related complications as determined by serial echocardiogram
Conditions Studied
Interventions
- COMBINATION_PRODUCT Tissue Engineered Vascular Grafts
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT04467671 shows while recruiting
NCT04467671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Tissue Engineered Vascular Grafts is the first listed.
NCT04467671 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04467671 about?
NCT04467671 is a clinical study titled "Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts". A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
What is the current status of trial NCT04467671?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-07-15. Estimated completion is 2027-08.
What conditions does trial NCT04467671 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Single-ventricle, Heart Defects, Congenital, Cardiovascular Abnormalities, HLH - Hypoplastic Left Heart Syndrome.
What interventions are being tested in trial NCT04467671?
The interventions under investigation include: Tissue Engineered Vascular Grafts (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04467671?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467671 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04467671's enrollment target sits among peer trials
24 273rd of 300 higher than 25 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI